Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive infusion guidance for managing infusion-associated reactions in RRMS patients treated with Lemtrada
2014-000092-62Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Primary endpoint: Proportion of mild infusion-associated reactions. Started Jun 2014; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2014-000092-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000092-62.